Avidity Biosciences, Inc.

Avidity Biosciences, Inc. company information, Employees & Contact Information

Explore related pages

Avidity Biosciences, Inc. email format Avidity Biosciences, Inc. management contacts

Related company profiles:

DELIVERING ON OUR VISION Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people. Through this platform, we are pleased to share our ideas and company progress as we advance our science and overall mission to deliver breakthrough therapies to patients.

Company Details

Employees
491
Address
10578 Science Center Dr,
Industry
Biotechnology
Website
aviditybio.com
Keywords
drug discovery and development, nucleic acids, RNA, rare disease.
HQ
San Diego, California
Competitors
Vertex Pharmaceuticals, Ionis Pharmaceuticals, Inc., BridgeBio, Neurocrine Biosciences, Crinetics Pharmaceuticals, Travere Therapeutics, Sarepta Therapeutics, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Poseida Therapeutics, Inc..
Looking for a particular Avidity Biosciences, Inc. employee's phone or email?

Avidity Biosciences, Inc. Questions

News

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - Investing News Network

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society Investing News Network

Avidity Biosciences to Participate in Upcoming Investor Conference - Morningstar

Avidity Biosciences to Participate in Upcoming Investor Conference Morningstar

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PR Newswire

Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 - The AI Journal

Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 The AI Journal

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - cnhinews.com

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society cnhinews.com

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire

Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire

Avidity Biosciences Accelerates Path to First Drug Approval, Expands Leadership for 2025 Launch - Stock Titan

Avidity Biosciences Accelerates Path to First Drug Approval, Expands Leadership for 2025 Launch Stock Titan

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - PR Newswire

Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights PR Newswire

Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development | Journal of Medicinal Chemistry - ACS Publications

Structure–Activity Relationship of Antibody–Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody–siRNA Conjugates for Drug Development | Journal of Medicinal Chemistry ACS Publications

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress - PR Newswire

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress PR Newswire

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights - PR Newswire

Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights PR Newswire

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth - PR Newswire

Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth PR Newswire

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer - PR Newswire

Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer PR Newswire

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology - PR Newswire

Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology PR Newswire

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) - PR Newswire

Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) PR Newswire

FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 - PR Newswire

FDA Grants Fast Track Designation to AOC 1001 for the Treatment of Myotonic Dystrophy Type 1 PR Newswire

Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer - PR Newswire

Avidity Biosciences Appoints Sarah Boyce as Chief Executive Officer PR Newswire

Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference - PR Newswire

Avidity Biosciences Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference PR Newswire

Companies like Avidity Biosciences, Inc.

Alnylam Pharmaceuticals logo - Similar company to Avidity Biosciences, Inc.

Alnylam Pharmaceuticals

2.58K
Neurocrine Biosciences logo - Similar company to Avidity Biosciences, Inc.

Neurocrine Biosciences

1.98K
Crinetics Pharmaceuticals logo - Similar company to Avidity Biosciences, Inc.

Crinetics Pharmaceut...

510
Sarepta Therapeutics logo - Similar company to Avidity Biosciences, Inc.

Sarepta Therapeutics

1.37K
Poseida Therapeutics, Inc. logo - Similar company to Avidity Biosciences, Inc.

Poseida Therapeutics...

218
Ionis Pharmaceuticals, Inc. logo - Similar company to Avidity Biosciences, Inc.

Ionis Pharmaceutical...

1.27K
Acadia Pharmaceuticals Inc. logo - Similar company to Avidity Biosciences, Inc.

Acadia Pharmaceutica...

891
Vertex Pharmaceuticals logo - Similar company to Avidity Biosciences, Inc.

Vertex Pharmaceuticals

6.09K
Travere Therapeutics logo - Similar company to Avidity Biosciences, Inc.

Travere Therapeutics

438
BridgeBio logo - Similar company to Avidity Biosciences, Inc.

Bridgebio

778

Top Avidity Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant